RecruitingAtherosclerotic Cardiovascular Disease

Pelacarsen Roll-over Extension Program

Eligible age

18–100 yrs

Accepts

All genders

Locations

20 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This non-randomized, rollover extension study will provide post-trial access to pelacarsen (TQJ230) to participants who have successfully completed either of the double-blind parent studies (CTQJ230A12303 or CTQJ230A12304).

Sponsor: Novartis Pharmaceuticals

You may qualify if…

✓ Participants who have provided informed consent prior to initiation of any study-specific activities/procedures.
✓ Participants who have completed the parent study and received the assigned study treatment at the time of its completion

You may not qualify if…

✕ Participants who permanently discontinued the study treatment as mandated per protocol or due to adverse events in the parent study
✕ Any medical condition(s) in the investigator's opinion that may put the participant at risk or interfere with the study participation
✕ Participants who are receiving another investigational drug or device before the open-label treatment period
✕ Participants who have a known sensitivity to the study drug and are deemed as unsuited for the study by the investigator
✕ Other protocol-defined inclusion/exclusion criteria may apply.